Buradasınız

Anasayfa » Content

KRANİYOFARİNJİOMALI 38 OLGUNUN DEĞERLENDİRİLMESİ

Journal Name:

  • İstanbul Tıp Fakültesi Dergisi

Publication Year:

  • 2003

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Clinical and laboratory evaluation of patients with Craniopharyngioma. In this study we eva-luated 38 patients (16 women/ 22 men) admitted to our elinic, and craniopharyngioma was proved histologicaliy. Themean age was 31.24 + 15.42 years (12-73). The mean follow-up pe-riod of 29 patients were 79,55 ± 59,66 (12-228) months. Headache was the chief complaİnt. Tumor was localized in sella in 26.1 % of the patients, supraseliar regİon in 26.1 % and, exten-ding from sella to supraseliar rcgion in 13 % of the patients. In 21.7 % of patients tumor had eystic strueture. Surgical removal of the tumor was performed İn 22 (57.89%) patients, and ad-juvant radiotherapy in 9 (23.68%) of the patieiits. An primary modc of treatment radiolherapy was performed in 1, aspiratİon of the eyst in 2, and intracystic yttrium-90 iınplantation in 3 of the patients. Endocrİnologic deficiencies were inevİtablc after ali of the treatment modalİtİcs. Panhypopİtuitarism was detecled in 33% to 63% of the patients according to the treatment mo-dalities. Recurrence rate was 10,5% (4 cases). In conelusion the treatment modality seems to depend on the mass of the tumor and cndocrinologic deficiencies are unavoidable.
Bookmark/Search this post with
Abstract (Original Language): 
Bu çalışmada, 1983-2002 yılları arasında kliniğimize baş vuran, histopatolojik olarak kraniyo-farinjioma tanısı konmuş 38 olgu (16 kadın/ 22 erkek) retrospektif olarak incelenmiştir. Hastaların yaş ortalaması 31,24 ± 15,42 (12-73 arasında) dır. Takip edilen 29 hastada ortalama takip süresi 79,55 ± 59,66 (12-228) aydır. Geliş şikayetleri incelendiğinde cn sık yakınmanın baş ağrısı olduğu görülmüştür. Tümör, hastaların %26,1'inde intra-sellar, %26,1'inde supraseliar ve %13'ünde selladan supraseliar bölgeye yayılmakta, %21,7'si kistik niteliktedir. Tümör ek-sizyonu 22 (%57,89) hastada, adjuvan radyoterapi 9 hastada (%23,68) yapılmıştır. Bir olguda sadece radyoterapi, kistik yapıdaki 5 olgudan ikisinde aspirasyon, üçünde ise intratümöral yttrium-90 implantasyonu primer tedavi olarak uygulanmıştır. Tedavilerin sonucunda tüm olgularda çeşitli düzeylerde endokrinolojik yetersizlikler ortaya çıkmıştır. Panhipopituİtarİzm sıklığı seçilen tedaviye göre %33 ile %63 arasında bulunmuştur. Toplam 4 vakada (%10,50) nüks görülmüştür. Sonuç olarak seçilecek tedavi tümörün anatomik yapısına bağlı olup, gelişen endokrinolojik sekeller kaçınılmaz görünmektedir.
FULL TEXT (PDF): 
PDF icon arastirmax-kraniyofarinjiomali-38-olgunun-degerlendirilmesi.pdf
  • 1
59-64
  • Turkish

REFERENCES

References: 

1. Arafah BM, Nekl KE, Gold RS, Seiman WR: Dynamics of prolactm secretion in patients with hypopituitary mac-roadenomas. J Clin Endocrinol Metab 80:3507 (1995).
2. Baskİn DS, Wilson CB: Surgical managemenî of crani-opharyngiomas. J Neurosurg 65:22 (1986).
3. Rogol A.D: Hypotalamic and piîuitary disorders in in-fancy and childhood, "Principles and practice of endocri-nology and mctabolism, 3rd eddition, editör: Becker K.L, Lippincott Williams & Wilkins, Philadeiphia (200İ)", sayfa: 196
4. Bunin GR, Wilman PA, Preston-Martin S, Davis F, Bru-ner JM: The descriptive epidemiology of craniopharyngioma. J Neurosurg 89:547 (1998)
5. Bülow B, Attewell R, Hagmar L, Malmström CH, Er-furth EM: Posîoperative prognosis in craniopharyngioma with respect to cardiovascular mortality, survival, and tumor recurrence. J Clin Endocrinol Mctab. 83:3897 (1998).
6. Chiou SM, Lımsford LD, Niranjan A, Kondzioika D, Flickinger JC: Stereotactic radiosurgery of residual or re-current craniopharyngioma, after surgery, with or witho-utradiation teraphy. Neuro-oncoL 3:159 (2001)
7. Choux M, Lena G, Genitori L: Le craniopharyngioma de l'enfant. Neurochirurgie 37:12 (!991) (Abstract).
8. Crotty TB, Young WF, Davis DH, Shaw EG, Miller GM, Burger PC: Papillary craniopharyngioma: a cünicopath-hological study of 48 cases. J Neurosurg. 83:206 (1995).
9. Elwatidy SM, Jamjoom ZA, Jamjoom AB, Yakoub AO: Craniopharyngioma. Analysis of factors ttıat affect the oııtcome. Saudi Med J 23: 34 (2002) (Abstract).
10. Fahlbusch R, Paulus W, Huk W, Buschfeldcr M: Surgical treatment of craniopharyııgiomas: cxpcrience with 168 padenfs. J Neurosurg. 90:237 (1999).
11. Honegger J, Fahlbusch R: Surgicai treatment of craniıp-haryngiomas: endocrinological results, J Neurosurg. 90:251 (1999).
12. Isaac MA, Hahn SS, Kim JA, Bogart JA, Chung CT: Management of craniopharyngioma. Cancer. 7:516 (2001).
13. Jenkins JS, Gilbert J, Ang V: Hypotalamic-pituitary funetion in patients with craniopharyngiomas. J Clin Endocrinol Metab. 43:394 (1976).
14. Landoİt AM: Results of transsphenoidal extirpation of craniopharyngiomas and Rathke's eysts. Neurosurgcry. 28:410(1991).
15. Manaka S, Teramoto A, Takakura K: The efficancy of radioterapy for craniopharyngioma. J Neurosurg, 62:648 (1985).
16. Petito CK, Earlc KM: Craniopharyngiomas:a clinical and pathological revicw. Cancer 37: 1944 (1976).
17. Rajan B, Ashley S, Gorman C: Craniopharyngioma: long term results fo!lowing Iimited surgery and radioterapy. Radiother Oncol. 26:1 (1993).
18. Shin LJ, Asa S.S, Woodhousc L.J, Smyth HS, Ezzat S: Cystic lesions of the pituitary: clinicopalhologicai featu-res distinguishing craniopharyngioma, Rathke's ciefl eysts, and arachnoid eyst. J Clin Endocrinol Metab. 84(il):3972(1999).
19. Voeiker JL, Muller J: Clinical, radiographic and patholo-gica! features of symptomatic Rathke's cleft eysts. J Neurosurg. 74:535 (1991).
20. Yu X, Liu Z, Li S: Combined treatment with steriotactic intracavitary irradiation and gamma knife surgery for craniopharyngiomas. Stereolact Funct Neurosurg.75:117 (2000) (Abstract).
21. Yu X, Zhou D, Liu Z: Combİnation treatment for craniopharyngiomas with steriotactic intracavitary irradiation and gamma knife surgery. Zhounghua Yİ Wue Za Zhi.81(2):86 (2001) (Abstract).

Thank you for copying data from http://www.arastirmax.com